DGAP-News

Sangui BioTech International Inc.: Lower revenues in the third quarter

DGAP-News: Sangui BioTech International Inc. / Key word(s): Quarter
Results
Sangui BioTech International Inc.: Lower revenues in the third quarter

15.05.2015 / 12:00

---------------------------------------------------------------------


SanguiBioTech: Lower revenues in the third quarter

Witten, Germany Mai 15, 2015 - For the nine months (as of March 31, 2015)
of its 2015 financial year Sangui BioTech International, Inc. reports
revenues from product sales and royalties in the amount of USD116,560, an
increase of 29.9% over the revenues in the first nine months of the
financial year 2014 when revenues amounted to USD89,741 (previous period
numbers not adjusted for exchange rate changes). In the third quarter
(January through March 2015) revenues amounted to USD11,654 a decrease of
62.6% as compared with the most recent quarter(October through December
2014). According to information provided by global licensee SastoMed GmbH
revenues from license fees are expected to increase significantly over the
remaining quarters of the calendar year after the slump of the March
quarter.

Research and development expenses amounted to USD171,427 (9M/2014:
USD139,978). The increase is due to the preclinical trials which
demonstrated the functionality of Sangui's technology with respect to the
septic shock indication. The net loss attributable to shareholders of the
parent company came to USD537,282 (9M/2014: USD1,257,727). In the
respective period of the previous year, this position included the loss
incurred from the write down of a loan extended to an unrelated party. The
cash outflow from operations during the nine months amounted to USD445,557
(9M/2014: USD452,192).

As of December 31, 2014, the equity ratio was minus 113.6% (June 30, 2014:
2.8%).

In the course of the third quarter, the series of preclinical trials at
Giessen University inview of the indication septic shock was concluded
successfully. Sangui is currently preparing the next steps in the
preclinical development of its SBT102 product. An essential sub-project
will be the establishment of the final manufacturing process for the test
substance and eventually for an industry scale production.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]



---------------------------------------------------------------------

15.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


357523 15.05.2015